|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients显示文摘AIM: To assess pre-orthotopic liver transplantation (OLT) factors that could be evaluated pre-operatively or con- trolled post-operatively associated with hepatocellular carcinoma (HCC) recurrence and disease-free survival after liver transplantation (LT).METHODS: Four hundred and twelve patients trans- planted for HCC between 1988 and 1998 in 14 French centers, who survived the postoperative period were studied. Kaplan Meier estimates were calculated for 24 variables potentially associated with recurrence of HCC. Uni- and multivariate analyses were conducted to iden- tify independent predictors of recurrence. RESULTS: Overall 5-year disease-free survival was 57.1%. By univariate analysis, variables associated with disease-free survival were: presence of cirrhosis (P = 0.001), etiology of liver disease (P = 0.03), α fetoprotein level (< 200, 200 to 2000, or > 2000; P < 0.0001), γ-GT activity (N, N to 2N or > 2N; P = 0.02), the number of nodules (1, 2-3 or ≥ 4; P = 0.02), maximal diameter of the largest nodule (< 3 cm, 3 to 5 cm or > 5 cm; P < 0.0001), the sum of the diameter of the nodules (< 3 cm, 3 to 5 cm, 5 to 10 cm or >10 cm; P < 0.0001), bi- lobar location (P = 0.01), preoperative portal thrombosis (P < 0.0001), peri-operative treatment of the tumor (P = 0.002) and chemoembolization (P = 0.03), tumor differentiation (P = 0.01), initial type of calcineurin inhibitor (P = 0.003), the use of antilymphocyte antibodies (P = 0.02), rejection episodes (P = 0.003) and period of LT (P < 0.0001). By multivariate analysis, 6 variables were independently associated with HCC recurrence: maximal diameter of the largest nodule (P < 0.0001), time of LT (P < 0.0001), tumor differentiation (P < 0.0001), use of anti-lymphocyte antibody (ATG) or anti-CD3 antibody (OKT3) (P = 0.005), preoperative portal thrombosis (P = 0.06) and the number of nodules (P = 0.06). CONCLUSION: This study identif ies immunosuppression, through the use of ATG or OKT3, as a predictive factor of tumor recurrence, and confi rms the prognostic value of tumor differentiation. | Thomas Decaens Franoise Roudot-Thoraval Solange Bresson-Hadni Carole Meyer Jean Gugenheim Francois Durand Pierre-Henri Bernard Olivier Boillot Philippe Compagnon Yvon Calmus Jean Hardwigsen Christian Ducerf Georges Philippe Pageaux Sébastien Dharancy Olivier Chazouillères Daniel Cherqui Christophe Duvoux | 2006 | World Journal of Gastroenterology2006，12，45： | 10 |
| 2 | Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma显示文摘BACKGROUND Liver cancer is the fifth most common cancer and the second cause of cancerrelated deaths worldwide.Transarterial chemoembolization(TACE)is the best treatment of intermediate hepatocellular carcinoma(HCC).Doxorubicin is the most commonly used drug despite a low level of evidence.AIM To compare the objective response rate of idarubicin-based TACE(Ida-TACE)against doxorubicin-based TACE(Dox-TACE)in intermediate stage HCC.METHODS Between January 2012 and December 2014,all patients treated with TACE at our academic hospital were screened.Inclusion criteria were patients with Child-Pugh score A or B,a performance status below or equal to 1,and no prior TACE.Either lipiodol TACE or drug-eluting beads TACE could be performed with 10 mg of idarubicin or 50 mg of doxorubicin.Each patient treated with idarubicin was matched with two doxorubicin-treated patients.The TACE response was assessed by independent radiologists according to the mRECIST criteria.RESULTS Sixty patients were treated with doxorubicin and thirty with idarubicin.There were 93%and 87%of cirrhotic patients and 87%and 70%of Child-Pugh A in the doxorubicin and idarubicin groups,respectively.The median number of HCC per patient was two in both groups with 31%and 26%of single nodules in doxorubicin and idarubicin groups,respectively.Objective response rate after first TACE was 76.7%and 73.3%(P=0.797)with 41.7%and 40.0%complete response in doxorubicin and idarubicin groups,respectively.Progression-free survival was 7.7 mo in both groups,and liver transplant-free survival was 24.9 mo and 21.9 mo in doxorubicin and idarubicin groups,respectively.Safety profiles were similar in both groups,with grade 3-4 adverse events in 35%of Dox-TACE and 43%of Ida-TACEs.CONCLUSION Ida-TACE and Dox-TACE showed comparable results in terms of efficacy and safety.Ida-TACE may represent an interesting alternative to Dox-TACE in the management of patients with intermediate stage HCC. | Gael Stephane Roth Yann Teyssier Melodie Abousalihac Arnaud Seigneurin Julien Ghelfi Christian Sengel Thomas Decaens | 2020 | World Journal of Gastroenterology2020，26，3： | 3 |
| 3 | A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection显示文摘 | Jean–Charles Nault Aurélien De Reyniès Augusto Villanueva Julien Calderaro Sandra Rebouissou Gabrielle Couchy Thomas Decaens Dominique Franco Sandrine Imbeaud Francis Rousseau Daniel Azoulay Jean Saric Jean–Frédéric Blanc Charles Balabaud Paulette Bioulac | 2013 | Gastroenterology2013，，1： | 3 |
| 4 | Liver Resection for Transplantable Hepatocellular Carcinoma: Long-Term Survival and Role of Secondary Liver Transplantation显示文摘 | Daniel Cherqui Alexis Laurent Nicolas Mocellin Claude Tayar Alain Luciani Jeanne Tran Van Nhieu Thomas Decaens Monika Hurtova Riccardo Memeo Ariane Mallat Christophe Duvoux | 2009 | Annals of Surgery2009，，5： | 2 |
| 5 | Carbon and nitrogen dynamics in ageing earthworm casts in grasslands of the eastern plains of Colombia 显示文摘 | DECAENS T RANGEL A F ASAKAWA N THOMAS R J | 1999 | Biology and Fertility of Soils1999，30，1： | 1 |
| 6 | Liver Resection for Transplantable Hepatocellular Carcinoma: Long-Term Survival and Role of Secondary Liver Transplantation显示文摘 | Daniel Cherqui Alexis Laurent Nicolas Mocellin Claude Tayar Alain Luciani Jeanne Tran Van Nhieu Thomas Decaens Monika Hurtova Riccardo Memeo Ariane Mallat Christophe Duvoux | 2009 | Annals of Surgery2009，，5： | 1 |
| 7 | Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria显示文摘 | Christophe Duvoux Fran?oise Roudot–Thoraval Thomas Decaens Fabienne Pessione Hanaa Badran Tullio Piardi Claire Francoz Philippe Compagnon Claire Vanlemmens Jérome Dumortier Sébastien Dharancy Jean Gugenheim Pierre–Henri Bernard René Adam Sylvie Radenne Fa | 2012 | Gastroenterology2012，，4： | 1 |
| 8 | Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma显示文摘 | Thomas Decaens Alain Luciani Emmanuel Itti Anne Hulin Fran?oise Roudot-Thoraval Alexis Laurent Elie Serge Zafrani Ariane Mallat Christophe Duvoux | 2012 | Digestive and Liver Disease2012，，7： | 1 |
| 9 | Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization显示文摘BACKGROUND At the diagnosis of hepatocellular carcinoma(HCC),more than 90%of HCC patients present cirrhosis,a clinical condition often associated to malnutrition.Sarcopenia is an indirect marker of malnutrition assessable on computed tomography(CT).AIM To evaluate the prognostic value of sarcopenia in patients with HCC treated by trans-arterial(chemo)-embolization.METHODS Patients with HCC treated by a first session of trans-arterial(chemo)embolization and an available CT scan before treatment were included.Sarcopenia was assessed using skeletal muscle index at baseline and at the first radiological assessment.Radiological response was recorded after the first session of treatment using mRECIST.RESULTS Of 225 patients treated by trans-arterial bland embolization(n=71)or trans-arterial chemoembolization(n=154)for HCC between 2007 and 2013,Barcelona Clinic of Liver Cancer stage was A,B,and C in 27.5%,55%,and 16.8%of cases,respectively.Sarcopenia was present in 57.7%of the patients.Patients with sarcopenia presented a higher rate of progressive disease(19%vs 8%,P=0.0236),a shorter progression-free survival(8.3 vs 13.2 mo,P=0.0035),and a shorter median overall survival(19.4 mo vs 35.5 mo,P=0.0149)compared with non-sarcopenic patients.Finally,patients whose sarcopenia appeared after first transarterial treatment had the worst prognosis(P=0.0004).CONCLUSION Sarcopenia is associated with tumor progression and poor survival outcomes after trans-arterial(chemo)-embolization for HCC. | Gael Roth Yann Teyssier Maxime Benhamou Mélodie Abousalihac Stefano Caruso Christian Sengel Olivier Seror Julien Ghelfi Arnaud Seigneurin Nathalie Ganne-Carrie Elia Gigante Lorraine Blaise Olivier Sutter Thomas Decaens Jean-Charles Nault | 2022 | World Journal of Gastroenterology2022，28，36： | 1 |
| 10 | Liver Resection For Hepatocellular Carcinoma in 313 Western Patients: Tumor Biology and Underlying Liver Rather than Tumor Size Drive Prognosis显示文摘 | Michael D. Kluger Juan A. Salceda Alexis Laurent Claude Tayar Christophe Duvoux Thomas Decaens Alain Luciani Jeanne Tran Van Nhieu Daniel Azoulay Daniel Cherqui | 2014 | Journal of Hepatology2014，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员